CHF257.00
0.27%
SIX Swiss Exchange, Dec 06, 05:30 pm CET
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Roche Stock price

CHF257.00
-7.20 2.73% 1M
+18.90 7.94% 6M
+12.50 5.11% YTD
+7.05 2.82% 1Y
-110.55 30.08% 3Y
-48.35 15.83% 5Y
-36.60 12.47% 10Y
SIX Swiss Exchange, Closing price Fri, Dec 06 2024
+0.70 0.27%
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Key metrics

Market capitalization CHF204.77b
Enterprise Value CHF234.34b
P/E (TTM) P/E ratio 19.29
EV/FCF (TTM) EV/FCF 20.06
EV/Sales (TTM) EV/Sales 3.99
P/S ratio (TTM) P/S ratio 3.48
P/B ratio (TTM) P/B ratio 7.08
Dividend yield 3.74%
Last dividend (FY23) CHF9.60
Revenue growth (TTM) Revenue growth -3.26%
Revenue (TTM) Revenue CHF58.79b
EBIT (operating result TTM) EBIT CHF16.46b
Free Cash Flow (TTM) Free Cash Flow CHF11.68b
EPS (TTM) EPS CHF13.32
P/E forward 15.46
P/S forward 3.37
EV/Sales forward 3.86
Show more

Create a Free Account to create an Roche alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Analyst Opinions

22 Analysts have issued a Roche forecast:

9x Buy
41%
9x Hold
41%
4x Sell
18%

Analyst Opinions

22 Analysts have issued a Roche forecast:

Buy
41%
Hold
41%
Sell
18%

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
58,785 58,785
3% 3%
100%
- Direct Costs 15,912 15,912
4% 4%
27%
42,873 42,873
3% 3%
73%
- Selling and Administrative Expenses 9,826 9,826
5% 5%
17%
- Research and Development Expense 13,205 13,205
4% 4%
22%
19,842 19,842
6% 6%
34%
- Depreciation and Amortization 3,378 3,378
8% 8%
6%
EBIT (Operating Income) EBIT 16,464 16,464
5% 5%
28%
Net Profit 10,619 10,619
4% 4%
18%

In millions CHF.

Don't miss a Thing! We will send you all news about Roche directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roche Stock News

Neutral
Business Wire
about 12 hours ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma...
Neutral
GlobeNewsWire
about 12 hours ago
Basel, 8 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session a...
Neutral
Business Wire
4 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people with relapsed or refracto...
More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Thomas Schinecker
Employees 103,605
Founded 1896
Website www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today